Nalaganje...
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have...
Shranjeno v:
| izdano v: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6938196/ https://ncbi.nlm.nih.gov/pubmed/31920338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S195552 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|